Follicular lymphoma (FL) is entering a new era: from decades of chemotherapy to increasingly effective, less toxic biological and immunotherapy-based approaches.
In this podcast episode of EHA Unplugged, hear directly from the authors of the latest EHA guidelines on FL: Prof Marco Ladetto (University of Eastern Piedmont, Italy) and Prof Martin Dreyling (LMU Munich, Germany).
They start by discussing the importance of histological confirmation and grading, the role—and current limits—of molecular profiling, and how FLIPI-based risk assessment can inform treatment intensity.
The conversation covers active surveillance for asymptomatic disease, first-line immunochemotherapy, chemo-free options such as rituximab–lenalidomide and novel antibody-based combinations, and sequencing CAR T-cell therapy and bispecific antibodies in later relapses.
The experts also address survivorship, long-term toxicity, patient preferences, and the strategic need to preserve effective options across a potentially decades-long disease course.
Tune in for practical, evidence-based insights to support individualised follicular lymphoma care.
Guests:
Prof Marco Ladetto
University of Eastern Piedmont and SCDU Ematologia, Alessandria, Italy
Prof Martin Dreyling
Ludwig-Maximilian-University, Munich, Germany
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
